Less Ads, More Data, More Tools Register for FREE

Pin to quick picksForterra Regulatory News (FORT)

Share Price Information for Forterra (FORT)

Share Price is delayed by 15 minutes
Get Live Data
133.40    1.80 (1.37%)
Bid:
133.20
Ask:
133.80
Spread: 0.60 (0.45%)
Market Cap: £272.52m
FORT Live PriceLast checked at - London Stock Exchange

Intraday Forterra Share Chart

Director/PDMR Shareholding

15 Jun 2021 09:56

RNS Number : 9401B
Forterra plc
15 June 2021
 

15 June 2021

Forterra plc (the "Company")

Director / PDMR Shareholdings

Following the vesting on 26 April 2018 of share options granted to to certain senior managers including persons discharging managerial responsibility ("PDMRs") under the 2016 Deferred Annual Bonus Plan ("DABP"), the Company was notified on the 14 June 2021 that on the same day the following exercise took place:

Adam Smith, Commercial Director exercised options granted under the DABP as laid out below and paid the appropriate tax and national insurance liabilities separately.

Name

Status

Number of shares exercised

Exercise Date

Number of shares retained

Beneficial interest

% of ISC

Adam Smith

PDMR

17,306

14/6/21

17,306

35,767

< 1%

The 2016 DABP awards represent the deferral into ordinary shares of the IPO Bonus to which those individuals become entitled to following the successful admission of the Company's ordinary share capital to the Official List of the Financial Conduct Authority and to trading on the London Stock Exchange plc's main market for listed securities, which occurred on 26 April 2016, as disclosed in the Company's prospectus (the "Prospectus") dated 21 April 2016 subject to the participant being an employee at the time of vesting.

No consideration was paid for the grant of the awards which are structured as nominal (1p) cost options although this sum was waived by the Company on exercise. The number of options exercised also includes a dividend equivalent in addition to the options initially granted in accordance with the rules of the scheme.

No new shares were issued in respect of these transactions with shares being transferred to the individuals from the Forterra Employee Benefit Trust.

The above notification is intended to satisfy the Company's obligations under Article 19 of the Market Abuse Regulations.

Enquiries

Forterra plc:

+44 (0) 1604 707 600

Ashley Thompson (Company Secretary)

FTI Consulting:

+44 (0) 20 3727 1340

Richard Mountain/Nick Hasell

Further information relating to the Company and its group can be found at www.forterraplc.co.uk.

1.

Details of the person discharging managerial responsibilities/person closely associated

a)

Name

Adam Smith

2.

Reason for the notification

a)

Position/status

PDMR (Commercial Director)

b)

Initial notification/Amendment

Initial notification

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Forterra plc

b)

LEI

213800O5DD6ATBVJAD23

4.

Details of the transaction(s):

a)

Description of the financial instrument, type of instrument

Identification code

Ordinary Shares of 1p each

 

GB00BYYW3C20

b)

Nature of the transaction

Acquisition of shares for no consideration pursuant to the exercise of nominal cost options (with the 1p option cost waived by the Company) granted under the DABP scheme on 1 June 2016 and vesting on 26 April 2018

c)

Price(s) and volume(s)

Transaction

Price(s)

Volume(s)

 

£Nil

 

 

£Nil

 

17,306 options vesting

 

17,306 shares acquired

d)

Aggregated information

 

Transaction

Price(s)

Volume(s)

Total

 Exercise

£Nil

17,306

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHGPUWAQUPGURA
Date   Source Headline
16th Mar 202610:32 amRNSLaunch of £20m Share Buyback Programme
11th Mar 20267:00 amRNSFull Year Results
3rd Mar 20263:27 pmRNSEmployee Benefit Trust Share Purchase
18th Feb 20262:27 pmRNSEmployee Benefit Trust Share Purchase
3rd Feb 202612:26 pmRNSEmployee Benefit Trust Share Purchase
29th Jan 20268:33 amRNSHolding(s) in Company
28th Jan 20269:21 amRNSHolding(s) in Company
26th Jan 20264:07 pmRNSHolding(s) in Company
22nd Jan 20267:00 amRNSFull Year 2025 Trading Update
20th Jan 20267:00 amRNSEmployee Benefit Trust Share Purchase
7th Jan 20269:39 amRNSEmployee Benefit Trust Share Purchase
2nd Dec 20259:22 amRNSEmployee Benefit Trust Share Purchase
24th Nov 20259:03 amRNSHolding(s) in Company
20th Nov 20259:13 amRNSHolding(s) in Company
18th Nov 20255:03 pmRNSEmployee Benefit Trust Share Purchase
11th Nov 20257:00 amRNSTrading Update
4th Nov 20254:34 pmRNSEmployee Benefit Trust Share Purchase
24th Oct 20251:36 pmRNSHolding(s) in Company
23rd Oct 20251:21 pmRNSDirector/PDMR Shareholding
17th Oct 20259:58 amRNSEmployee Benefit Trust Share Purchase
14th Oct 20259:06 amRNSHolding(s) in Company
13th Oct 202510:15 amRNSEmployee Benefit Trust Share Purchase
2nd Oct 20252:54 pmRNSGrant of Options under 2025 SAYE Scheme
11th Aug 20251:15 pmRNSHolding(s) in Company
29th Jul 20257:38 amRNS-RProgressive publishes new research
29th Jul 20257:00 amRNSSix months ended 30 June 2025
23rd Jul 202510:05 amRNSHolding(s) in Company
19th Jun 20257:05 amRNSDirector Declaration
20th May 20251:47 pmRNSAnnual General Meeting 2025 Results
20th May 20257:43 amRNS-RProgressive publishes new research
20th May 20257:00 amRNSAGM Trading Update
13th May 202510:36 amRNSHolding(s) in Company
11th Apr 20259:18 amRNSDirector / PCA Shareholdings
2nd Apr 20252:22 pmRNSDirector/PDMR Shareholding
26th Mar 20255:53 pmRNSAnnual Report & Accounts 2024 & Notice of AGM 2025
25th Mar 20251:47 pmRNSDirector/PDMR Shareholding
20th Mar 20252:44 pmRNSHolding(s) in Company
20th Mar 20257:00 amRNSGrant under Performance Share Plan
20th Mar 20257:00 amRNSGrant under Deferred Annual Bonus Plan
18th Mar 20252:23 pmRNSHolding(s) in Company
12th Mar 20258:14 amRNS-RProgressive publishes new research
12th Mar 20257:00 amRNSFull Year Results
6th Mar 20257:00 amRNSAppointment of Independent Non-Executive Director
27th Feb 20253:35 pmRNSHolding(s) in Company
26th Feb 20252:50 pmRNSHolding(s) in Company
4th Feb 20257:00 amRNSDirectorate Change
23rd Jan 20257:00 amRNSFull Year 2024 Trading Update
6th Jan 20259:23 amRNSHolding(s) in Company
2nd Jan 202511:38 amRNSDirector/PDMR Shareholding
11th Nov 20247:00 amRNSTrading update to the end of the October

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.